Management of vernal keratoconjunctivitis: Navigating a changing treatment landscape

Ali, Asim; Bielory, Leonard; Dotchin, Stephanie; Hamel, Patrick; Strube, Yi Ning J.; Koo, Euna B.

doi:10.1016/j.survophthal.2023.10.008

Search citation statements

Order By: Relevance

Paper Sections

Select...

Treatment Of Vernal Keratoconjunctivitis Using Upadacitinib1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As severe cases are often refractory to topical treatment using steroids or immunosuppressants, the development of novel therapeutic strategies is imperative. [1][2][3] Janus kinase (JAK), an intracellular tyrosine kinase, regulates cytokine signaling pathways. Currently, JAK inhibitors are used to treat atopic dermatitis (AD).…”

Section: Treatment Of Vernal Keratoconjunctivitis Using Upadacitinibmentioning

confidence: 99%

“…Clinically, VKC is characterized by the formation of giant papillae on the upper palpebral conjunctiva and corneal damage caused by potent type 2 and eosinophilic inflammation, resulting in vision loss. As severe cases are often refractory to topical treatment using steroids or immunosuppressants, the development of novel therapeutic strategies is imperative . Janus kinase (JAK), an intracellular tyrosine kinase, regulates cytokine signaling pathways.…”

mentioning

confidence: 99%

See 1 more Smart Citation